What are the cons of Opzelura?

0 votes
asked Jan 30, 2024 in Body/Skin by Ariannar (2,080 points)
What are the cons of Opzelura?

1 Answer

0 votes
answered May 19, 2024 by Adf289 (61,630 points)
The cons of Opzelura are the possible serious side effects that it can cause which include cancer and immune system problems, blood clots, low blood cell counts, increase in cholesterol and serious infections.

Also people that have taken JAK inhibitors by mouth also had an increased risk of death.

You should use Opzelura for up to 8 weeks and if it is not working then you should let your doctor know.

You cannot buy Opzelura over the counter as Opzelura requires a prescription from your doctor.

Opzelura is a topical skin medication that is used for short term chronic treatment of moderate or mild eczema in adults and children that are 12 years or older who are not immunocompromised.

The cost of Opzelura cream is $36.05 for 60 grams or around $2,162.89 for complete treatment.

ELIGIBLE PATIENTS WITH COMMERCIAL INSURANCE MAY PAY AS LITTLE AS $0 PER TUBE FOR OPZELURA.

Through the OPZELURA copay savings program, you may be able to pay as little as $0 on every tube.

OPZELURA has been proven to provide clear or almost clear skin and significantly reduce itch.

Some even saw rapid itch improvement as early as 3 or 4 days.

Results may vary.

OPZELURA will not work for everyone.

In a medical study of mild to moderate AD, 54% of patients had clear to almost clear skin at 8 weeks and 52% of patients had a significant reduction in their itch, compared to 15% of patients who used a cream that did not contain medication.

And because Opzelura is not a TCS, it is able to be used over a longer period of time (up to 8 weeks), and on body areas that are more delicate or have thinner skin such as the face, eyelids, genitals, or skin folds, where TCS use is not preferred.

In September 2021 , Opzelura was approved by the FDA for the topical short-term and non-continuous chronic treatment of mild to moderate atopic dermatitis (AD) in non-immunocompromised patients 12 years of age and older whose disease is not adequately controlled with topical prescription therapies.

Ruxolitinib belongs to a class of medicines called Janus kinase (JAK) inhibitors. JAK inhibitors are medicines that affect your immune system.

JAK inhibitors can lower the ability of your immune system to fight infections.

108,712 questions

117,619 answers

1,356 comments

7,058,495 users

...